Boron neutron capture therapy of cerebral gliomas. II. Utilization of the blood-brain barrier and tumor-specific antigens for the selective concentration of boron in gliomas

• Published in: Oncology Vol. 32; no. 5-6; p. 223
• Main Authors: Tolpin, E I, Wellum, G R, Dohan, Jr, F C, Kornblith, P L, Zamenhof, R G
• Format: Journal Article
• Language: English
• Published: Switzerland 1975
• Subjects: Animals; Antibodies, Neoplasm; Antigens, Neoplasm; Binding Sites, Antibody; Blood-Brain Barrier; Boranes - metabolism; Boron - blood; Boron - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - immunology; Brain Neoplasms - metabolism; Disease Models, Animal; Glioblastoma - drug therapy; Glioblastoma - immunology; Glioblastoma - metabolism; Isotopes; Male; Neoplasms, Experimental - drug therapy; Radiotherapy Dosage; Rats
• ISSN: 0030-2414; 1423-0232
• DOI: 10.1159/000225073

The use of the blood-brain barrier and of tumor-specific antibodies to concentrate boron selectivity in gliomas for neutron capture therapy is considered experimentally and theoretically. The time-dependent concentration of two anionic boranes, B12 H11 SH2- and B12 H11 SOSB12 H114-, in the blood, brain, and tumor of rats bearing a tumor of gliomatous origin is reported. The rate of clearance of each anionic borane from the blood is correlated with the fraction of non-protein bound anion in the plasma. The use of antibodies to carry therapeutical useful amounts of boron to tumor-specific or tumor-associated antigens on the tumor cell surface will require different numbers of boron atoms bound per antibody depending on several immunological and physical parameters. Calculations using published values of antibody-antigen association constants and of cell surface antigen densities predict that in order to obtain 10mug 10B/g tumor from 10 to over 10,000 boron-10 atoms will have to be bound per tumor antigenic site.